Axio BioPharma

Based in Wisconsin, US, Axio BioPharma Inc. was founded in 2024 by Justin Byers (Founder, CEO) and Brian Staats (Co-founder, CTO). As of September 2026, the company is led by its CEO, Justin Byers. In September 2026, the company closed a USD 2.

4 million pre-seed financing round with participation from Elmstead Partners, Chisos Capital, Chemical Angel Network and Individual Investor. The company operates Axio Forge, a non-GMP high-throughput monoclonal antibody laboratory in Madison that produces approximately 100 antibodies per week with a three-to-five-week turnaround from sequence or plasmid, offering transient CHO and HEK293 expression, Protein A purification and standard analytics. It is also developing Axio Lattice, a vendor-neutral federated data platform that connects manufacturing data across pharma sponsors and manufacturing partners without centralizing data, together with Rosetta, its ontology mapping layer. It serves biotech and pharmaceutical companies and contract development and manufacturing organizations.

The company generates fee-for-service revenue from Axio Forge antibody production and plans recurring subscription revenue from Axio Lattice. The company plans to use its September 2026 funding to support initial deployments of Axio Lattice and continued development of Rosetta, working directly with design partners to address cross-company data gaps in areas including tech transfer and investigations.